Top-Line Revenue Growth
Total revenue of $310 million in Q1 FY2026, up 15% year-over-year and finishing at the upper end of prior guidance.
Product and Service Revenue Strength
Product revenue of $175 million, up 20% year-over-year; Service revenue of $135 million, up 8% year-over-year, with recurring revenue expansion driven by Specialty and Consumables.
Material Profitability Improvement
Non-GAAP EBITDA of $45 million versus $24 million a year ago (≈+88%), non-GAAP EPS of $0.55 versus $0.26 in prior year, and GAAP EPS of $0.25 versus a loss of $0.15 a year ago.
Improving Gross and Free Cash Metrics
Non-GAAP gross margin ~46% (versus 42% in Q1 FY2025 and 44% FY2025); Free cash flow of $39 million in Q1 versus $10 million year-over-year (≈+290%).
Strengthened Guidance and Financial Targets
Maintained full-year product bookings guidance of $510M–$560M and raised full-year non-GAAP EBITDA to $153M–$168M (from $145M–$165M) and non-GAAP EPS to $1.80–$2.00 (from $1.65–$1.85). Full-year revenue guidance $1.215B–$1.255B and year-end ARR guidance $680M–$700M.
Strategic Product Launch and Early Traction
Announced Omnicell Titan XT and OmniSphere platform; initial Titan XT orders booked in Q1; hardware shipment planned H2 2026 and phased OmniSphere rollout in H1 2027, with positive customer feedback on workflow and inventory benefits.
Commercial Momentum and Competitive Opportunity
Reported strong pipeline activity and competitive conversion opportunities (including expanded deployments with the U.S. Department of Veterans Affairs and a major academic medical center), with increased demo demand and enlarged commercial engagement.
Balance Sheet Actions and Capital Allocation
Repayment of $175 million of debt (matured Sept 2025) and prior repurchase of ~ $78 million of common stock; cash and cash equivalents were $239 million as of March 31, 2026.